Earnings call · Apr–Jun 2026
Sun Pharmaceutical Industries Ltd.
From the company
- Abhishek Sharma
- Jayashree Satagopan
- Kirti Ganorkar
- Richard Ascroft
- Aalok Shanghvi
- Dilip Shanghvi
Questions came from
- Amey ChalkeJM
- Damayanti KeraiHSBC
- Kunal DhameshaMacquarie
- Neha ManpuriaBank of America Securities
- Shashank KrishnakumarEmkay Global
- Bino PathiparampilElara Capital
- Saion MukherjeeNomura
- Shyam SrinivasanGoldman Sachs
- Surya Narayan PatraPhillipCapital India
- Foram ParekhBOB Capital Markets
- Abdulkader PuranwalaICICI Securities
- Vishal ManchandaSystematix
Topics in this call
Opening remarks
Abhishek Sharma
Thank you. Good evening, and a warm welcome to our first quarter FY27 earnings call. I'm Abhishek from the Sun Pharma Investor Relations team. We hope you have received the Q1 financials, the press release and the earnings presentation that was sent out earlier in the day. These are also available on our website.
We have with us Mr. Dilip Shanghvi, Chairman; Mr. Kirti Ganorkar, Managing Director; Mr. Aalok Shanghvi, Chief Operating Officer; Ms. Jayashree Satagopan, CFO; and Mr. Richard Ascroft, CEO, North America.
Read the whole call: 190 paragraphs, 13 analysts' questions with every answer.
Premium opens every call in full: the notes, the marked passages, search & topic jumps, for every company that files a transcript.
The transcript as the company filed it on BSE. Our own rules split it into speakers & sections; an unusual layout can trip them, so check the original PDF for anything important. Not a recommendation.